Indication
as monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy

Medicine details

Medicine name:
lenvatinib (Lenvima)
SMC ID:
SMC2138
Pharmaceutical company
Eisai Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full submission
Status
Advice due date:
Q2 2019
SMC meeting date:
Q2 2019
Patient group submission deadline:
04 February 2019